Salud Digna.
How Mexico’s largest nonprofit diagnostic network can scale without losing the mission that built it.
Team contributor
MBA capstone, 5-person team
Fall 2024 to Spring 2025
VRIODS, 7-factor plan
A thirty-second read.
Problem.
Salud Digna runs a 67% market-share low-cost diagnostic network across Mexico on an NGO model. Demand is exploding. Financial and leadership capacity are not. Scaling risks mission drift.
Role.
Team contributor. I led the VRIODS internal analysis, contributed to SWOT, co-authored final recommendations, and owned the 7-factor implementation plan.
Approach.
VRIODS, SWOT, TEA on CEO Hugo Moreno, Value Chain, Porter's Five Forces, evaluation of 12 strategic alternatives, financial impact modeling, and a 7-factor implementation plan.
Key insight.
Management capacity, not demand, is the binding constraint on pace. The McDonald's-of-healthcare analogy only works if the playbook is codified and enforced.
Recommendation.
Stay NGO. Hire a COO. Access $3M to $5M through social impact financing. Codify the operating model. Expand tomography services before entering cities under 100K.
Outcome (projected).
$1.1M annual operating surplus sustained. $3M to $5M external capital unlocked without debt obligation. 42% to 50% gross margin preserved. NGO tax and supplier advantages protected.
Demand is exploding. Capacity is not.
Salud Digna provides low-cost diagnostic healthcare to underprivileged Mexican citizens. Public health centers are overcrowded. Private clinics cost far more. Chronic disease, especially diabetes, is driving explosive demand for testing. Salud Digna holds 67% category share at prices competitors cannot profitably match.
The cracks are structural. CEO Hugo Moreno runs 80 direct reports each week, with no formal succession plan. Capital is tight. Imitators (Simi Lab, Mi Salud) are replicating the low-cost model. Banco Compartamos is pushing a for-profit conversion as a loan condition.
Three pressures stack on top of each other.
01
Management capacity.
Moreno has 80 weekly direct reports and no formal succession. A key-person risk that scales with every new clinic that opens.
02
Capital constraints.
The NGO model protects margin but limits financing. A for-profit conversion pitched as a loan condition would erode the supplier and tax economics that make the business work.
03
Imitable low-cost model.
Competitors can match the price. They cannot match the combination of brand trust, Roche supplier terms, and NGO status. The moat is the system, not the price.
The team’s job was to recommend a path that solved all three without destroying the thing that made Salud Digna work in the first place.
Two frameworks did most of the work.
The team ran six frameworks across the engagement. Two pointed cleanly at the answer. VRIODS surfaced that the moat is the system, not the low-cost model. SWOT made clear that the largest risk was management capacity failure, not demand.
Seven capabilities. Three sustainable advantages.
Supplier alliances (Roche).
Long-term contracts and volume terms competitors cannot match quickly. Reagent economics flow from this relationship.
Brand trust.
25 years of reputation with underprivileged patients. Trust of this kind cannot be bought in under a decade.
Mission culture.
Staff retention, patient loyalty, and operational discipline rooted in NGO identity. Shows up in every KPI.
Tomography capability.
$32.65 per procedure margin versus $1.51 for lab tests. Currently limited to Culiacan. Untapped revenue at scale.
Clinic network scale.
67% share and a physical footprint built over two decades. A well-capitalized entrant could catch up eventually.
NGO tax and supplier status.
Real structural advantage in tax treatment and supplier terms. Under active pressure from for-profit conversion demands.
Low-cost operating model.
Simi Lab and Mi Salud are already replicating the model. The price point is not the moat. The system around it is.
The low-cost model scored low on Rarity and Imitability. Supplier alliances, brand trust, and mission culture scored across the board. The moat is the combination, not the price point.
The largest risk is internal.
- 67% category market share in Mexico.
- 42 to 50% gross margin on a low-cost model.
- Roche supplier alliance. Cost advantage competitors cannot match.
- NGO status. Tax, supplier, and media advantages.
- CEO running 80 weekly direct reports.
- No formal succession plan. Key-person risk.
- Capital constrained. Limited access to debt.
- Tomography capability limited to Culiacan.
- Tomography margin expansion. $32.65 per procedure versus $1.51 for labs.
- $3M to $5M social impact financing (Gomez Mont precedent).
- Codify the operating playbook. McDonald's-style scaling.
- Chronic disease demand. Diabetes screening at scale.
- Imitators: Simi Lab, Mi Salud replicating the low-cost model.
- For-profit conversion pressure from Banco Compartamos.
- Hugo Moreno key-person risk without a successor.
- Cities under 100K population do not break even (Vista Hermosa).
Five moves, in order.
The sequence matters. Stay NGO first. Solve the management capacity crisis second. Then open access to capital and codify the playbook. Expansion is the last step, not the first.
Stay NGO.
Preserve tax, supplier, and media advantages. The conversion pressure from Banco Compartamos is a trap. The combined benefits of NGO status are worth more than the debt capital.
Hire a COO.
Solve Moreno's management capacity crisis. Free him for expansion strategy and external partnerships. Budget $80K to $120K per year. Requires NGO plus business experience.
Social impact financing.
Replicate the Gomez Mont donor-funded Mexico City clinic. Target $3M to $5M without debt obligation or for-profit conversion.
Codify the playbook first.
Document and enforce the operating model before the next clinic opens. Invest in technology and automation so efficiency gains compound with scale.
Tomography first, small cities last.
Grow operating surplus through the $32.65 margin service before entering cities under 100K population. Vista Hermosa closed in under a year. Sequence matters.
Seven factors, three lenses each.
Every recommendation mapped to a financial impact, an operational impact, and a mission-and-social impact. That table is the bridge between the analysis and the work of actually doing the thing.
$80K to $120K annual cost.
Reduces Moreno's span of control from 80 to 8 to 12.
Preserves founder-led culture through a codified handoff.
Unlocks capital without debt obligation.
Funds tomography expansion and playbook codification.
Avoids for-profit conversion pressure.
One-time build cost, amortized over every new clinic.
New clinic open time drops. Quality variance drops.
Patient experience holds as the network grows.
$32.65 per procedure margin. 20x lab-test margin.
Requires capex per site. Trained technicians.
Diagnostic access expands to harder clinical needs.
Maintains 42 to 50% gross margin.
Lock multi-year terms. Add a secondary supplier for risk.
Price to patient stays low.
Avoids Vista Hermosa-style closures.
Geographic expansion prioritizes density.
Mission served better by fewer sustainable clinics than many failing ones.
Modest planning cost.
Removes single-point-of-failure risk.
Institution outlives the founder. The McDonald's test.
What the recommendation buys.
Case recommendation, not shipped result. Numbers reflect the modeled outcome in the submitted analysis.
$1.1M
Sustained operating surplus under the recommended structure.
$3 to $5M
Social impact financing without debt obligation.
42 to 50%
Preserved through Roche supplier relationship protection.
80 to 12
Moreno's direct reports drop from 80 weekly to 8 to 12.
NGO
Tax, supplier, and media advantages protected.
67%
Category leadership against imitators Simi Lab and Mi Salud.
The punchline. The NGO is the advantage. Protect it. Then solve the management capacity crisis and let the codified playbook carry the growth.
Three things I would do differently.
The recommendation held up. The process did not always. Three calls I would make differently if I ran the engagement again.
- 01
Push harder on for-profit conversion earlier.
The team spent too long weighing the conversion alternative seriously. The VRIODS work had already shown the answer in week two. We should have compressed that discussion.
- 02
Model the Moreno succession question.
We recommended a COO hire but did not model what happens if Moreno leaves before the COO is in place. That is the real key-person risk.
- 03
Visit a clinic.
Everything we knew came from the Harvard case and secondary research. One day on the ground in Culiacan would have changed the recommendations on scaling.